ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
Recruiting · NCT04916613 · Registry updated 2026-04-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable) | metastatic prostate carcinoma | Recruiting | Phase 3 | 2026-04-28 | NCT04916613 |
2 results · Page 1 of 1
95 results · Page 1 of 4
Research sites
Swipe the table sideways for more columns.